Oxford Biomedica sees swing to FY profit on Covid vaccine hopes

By

Sharecast News | 17 Sep, 2020

Updated : 07:31

17:19 17/05/24

  • 323.50
  • -2.27%-7.50
  • Max: 334.00
  • Min: 320.00
  • Volume: 124,486
  • MM 200 : 466.83

Drugs maker Oxford Biomedica, which has partnered with pharma giant AstraZeneca to develop a Covid-19 vaccine, said it expected higher second half revenues to push it to a low-to-single digit full year profit.

Last news